Dr. Janice Mehnert highlights promising phase 3 results for a personalized mRNA-based therapy designed to help prevent high-risk melanoma from returning after surgery
This phase 3 study compares BRAF-targeted therapy (dabrafenib-trametinib) to TKI therapy (cabozantinib) in patients with disease progression after standard treatments